INVIVYD, INC. Other Nonoperating Gains (Losses)
INVIVYD, INC. (IVVD) reported Other Nonoperating Gains (Losses) of $1.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingGainsLosses · last filed 2026-08-13
- INVIVYD, INC. other nonoperating gains (losses) for the quarter ending 2026-06-30 was $1.43M, a 256.75% increase year-over-year.
- INVIVYD, INC. other nonoperating gains (losses) for the quarter ending 2026-03-31 was $1.74M, a 174.25% increase year-over-year.
- INVIVYD, INC. other nonoperating gains (losses) for the quarter ending 2025-12-31 was $1.49M, a 88.93% increase year-over-year.
- INVIVYD, INC. other nonoperating gains (losses) for the quarter ending 2025-09-30 was $553.00K, a 64.82% decline year-over-year.
- INVIVYD, INC. other nonoperating gains (losses) for fiscal 2025 was $3.07M, a 55.82% decline from fiscal 2024.
- INVIVYD, INC. other nonoperating gains (losses) for fiscal 2024 was $6.95M, a 50.75% decline from fiscal 2023.
- INVIVYD, INC. other nonoperating gains (losses) for fiscal 2023 was $14.12M, a 110.23% increase from fiscal 2022.
- INVIVYD, INC. other nonoperating gains (losses) for fiscal 2022 was $6.71M.
| Period end | Other Nonoperating Gains (Losses) 3 month | Other Nonoperating Gains (Losses) 3 month as first filed | Other Nonoperating Gains (Losses) 4 month | Other Nonoperating Gains (Losses) 6 month | Other Nonoperating Gains (Losses) 6 month as first filed | Other Nonoperating Gains (Losses) 7 month | Other Nonoperating Gains (Losses) 9 month | Other Nonoperating Gains (Losses) 9 month as first filed | Other Nonoperating Gains (Losses) 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.43M 10-Q · filed 2026-08-13 | $3.16M 10-Q · filed 2026-08-13 | $4.65M derived: sum of 3 quarters · filed 2026-08-13 | $5.20M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2026-03-31 | $1.74M 10-Q · filed 2026-05-14 | $3.22M derived: sum of 2 quarters · filed 2026-05-14 | $3.77M derived: sum of 3 quarters · filed 2026-05-14 | $4.17M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.04M derived: sum of 2 quarters · filed 2026-03-05 | $2.44M derived: sum of 3 quarters · filed 2026-08-13 | $3.07M 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | $553.00K 10-Q · filed 2025-11-06 | $953.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.59M 10-Q · filed 2025-11-06 | $2.37M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-13 | $1.03M 10-Q · filed 2026-08-13 | $1.82M derived: sum of 3 quarters · filed 2026-08-13 | $3.39M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-03-31 | $633.00K 10-Q · filed 2026-05-14 | $1.42M derived: sum of 2 quarters · filed 2026-05-14 | $2.99M derived: sum of 3 quarters · filed 2026-05-14 | $4.99M derived: sum of 4 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | $786.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.36M derived: sum of 2 quarters · filed 2026-03-05 | $4.36M derived: sum of 3 quarters · filed 2026-03-05 | $6.95M 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | $1.57M 10-Q · filed 2025-11-06 | $3.57M derived: sum of 2 quarters · filed 2025-11-06 | $6.17M 10-Q · filed 2025-11-06 | $9.26M derived: sum of 4 quarters · filed 2025-11-06 | |||||
| 2024-06-30 | $2.00M 10-Q · filed 2025-08-14 | $4.59M 10-Q · filed 2025-08-14 | $7.69M derived: sum of 3 quarters · filed 2025-08-14 | $11.31M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | $2.59M 10-Q · filed 2025-05-15 | $5.69M derived: sum of 2 quarters · filed 2025-05-15 | $9.31M derived: sum of 3 quarters · filed 2025-05-15 | $12.96M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $6.72M derived: sum of 2 quarters · filed 2025-03-20 | $10.37M derived: sum of 3 quarters · filed 2025-03-20 | $14.12M 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | $3.62M 10-Q · filed 2024-11-14 | $7.27M derived: sum of 2 quarters · filed 2024-11-14 | $11.02M 10-Q · filed 2024-11-14 | $14.65M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | $3.65M 10-Q · filed 2024-08-14 | $7.40M 10-Q · filed 2024-08-14 | $11.04M derived: sum of 3 quarters · filed 2024-08-14 | $13.28M derived: sum of 4 quarters · filed 2024-08-14 | |||||
| 2023-03-31 | $3.75M 10-Q · filed 2024-05-09 | $7.39M derived: sum of 2 quarters · filed 2024-05-09 | $9.63M derived: sum of 3 quarters · filed 2024-05-09 | $10.39M derived: sum of 4 quarters · filed 2024-05-09 | |||||
| 2022-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $5.88M derived: sum of 2 quarters · filed 2024-03-28 | $6.64M derived: sum of 3 quarters · filed 2024-03-28 | $6.71M 10-K · filed 2024-03-28 | |||||
| 2022-09-30 | $2.24M 10-Q · filed 2023-11-09 | $3.00M derived: sum of 2 quarters · filed 2023-11-09 | $3.08M 10-Q · filed 2023-11-09 | $3.12M derived: sum of 4 quarters · filed 2024-02-09 | |||||
| 2022-06-30 | $759.00K 10-Q · filed 2023-08-10 | $832.00K 10-Q · filed 2023-08-10 | $880.00K derived: sum of 3 quarters · filed 2024-02-09 | $923.00K derived: sum of 4 quarters · filed 2024-02-09 | |||||
| 2022-03-31 | $73.00K 10-Q · filed 2023-05-11 | $121.00K derived: sum of 2 quarters · filed 2024-02-09 | $164.00K derived: sum of 3 quarters · filed 2024-02-09 | $182.00K derived: sum of 4 quarters · filed 2024-02-09 | |||||
| 2021-12-31 | $48.00K derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | $91.00K derived: sum of 2 quarters · filed 2024-02-09 | $109.00K derived: sum of 3 quarters · filed 2024-02-09 | $118.00K 8-K · filed 2024-02-09 | |||||
| 2021-09-30 | $43.00K 10-Q · filed 2022-11-10 | -$5.00K 10-Q · filed 2021-11-15 | $61.00K derived: sum of 2 quarters · filed 2022-11-10 | $70.00K 10-Q · filed 2022-11-10 | -$10.00K 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $18.00K 10-Q · filed 2022-08-15 | -$5.00K 10-Q · filed 2021-09-20 | $26.00K 10-Q · filed 2022-08-15 | -$6.00K 10-Q · filed 2021-09-20 | |||||
| 2021-03-31 | $9.00K 10-Q · filed 2022-05-13 | ||||||||
| 2020-12-31 | $8.00K 10-K · filed 2022-03-31 | ||||||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |